{"id":2521,"date":"2025-08-23T14:58:10","date_gmt":"2025-08-23T14:58:10","guid":{"rendered":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/?p=2521"},"modified":"2025-08-23T14:58:10","modified_gmt":"2025-08-23T14:58:10","slug":"eli-lilly-seeks-new-neuroscience-leader-as-longtime-executive-anne-white-retires","status":"publish","type":"post","link":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/eli-lilly-seeks-new-neuroscience-leader-as-longtime-executive-anne-white-retires\/","title":{"rendered":"Eli Lilly Seeks New Neuroscience Leader as Longtime Executive Anne White Retires"},"content":{"rendered":"

Eli Lilly is looking for a new leader for its neuroscience division after announcing that Anne White, the current head, will retire at the end of December. White has spent 30 years at the Indianapolis-based pharmaceutical company. She took over the neuroscience division in 2021 when Lilly split its biomedicines unit to focus on new drugs for the immune system and Alzheimer<\/a>\u2019s disease. Before leading neuroscience, White was in charge of Lilly\u2019s cancer<\/a> division and helped successfully acquire and integrate Loxo Oncology<\/a>, which became key to Lilly\u2019s current cancer drug efforts. David Ricks, Lilly\u2019s CEO, praised White\u2019s dedication to developing treatments for some of the most difficult diseases. The company plans to consider both internal and external candidates to replace White, who will retire on December 31. As head of Lilly Neuroscience, White oversaw the approval and launch of Kisunla, a drug designed to slow Alzheimer\u2019s disease progression. This approval was a major milestone for Lilly, which had faced repeated setbacks in its Alzheimer\u2019s research before Kisunla. White has personally connected with this work, having written about her mother\u2019s experience with Alzheimer\u2019s and her hope that recent advances will lead to better treatments. In a Fortune editorial, she expressed optimism that progress in Alzheimer\u2019s research could also help with other brain diseases like ALS, Parkinson\u2019s, and multiple sclerosis. Recently, Lilly received FDA<\/a> approval for a modified dosing of Kisunla to reduce a potential side effect called ARIA, which has been a concern for similar drugs like Eisai and Biogen\u2019s Leqembi. While analysts expect Kisunla to eventually become a major success, its sales have been modest since its launch last year, with $49 million in revenue in the second quarter. Lilly is also developing another Alzheimer\u2019s drug, remternetug, which is currently in late-stage testing. The company\u2019s neuroscience pipeline includes gene therapies for Parkinson\u2019s, Gaucher disease, and frontotemporal dementia, as well as four new pain treatments. One of these pain therapies was recently added through Lilly\u2019s acquisition of SiteOne Therapeutics. Lilly also credited White with helping speed up drug development across the company.<\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly is looking for a new leader for its neuroscience division after announcing that Anne White, the current head, […]<\/p>\n","protected":false},"author":1,"featured_media":2522,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[543],"tags":[],"class_list":["post-2521","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-news"],"_links":{"self":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/2521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/comments?post=2521"}],"version-history":[{"count":1,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/2521\/revisions"}],"predecessor-version":[{"id":2543,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/2521\/revisions\/2543"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media\/2522"}],"wp:attachment":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media?parent=2521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/categories?post=2521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/tags?post=2521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}